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Introduction
　E1AF is an ets-oncogene family transcription 
factor that was cloned by the ability to bind the 
adenovirus E1A enhancer element1.  E1AF has a 
functional acidic domain, glutamine-rich domain 
and ets domain.  The ets domain is a unique 
amino acid sequence that is a feature of the ets-
oncogene family.  The ets domain of E1AF is situ-
ated in its C-terminal with 85 amino acids that 
have a helix-loop-helix structure with a trypto-
phane repeat.  Moreover, the ets domain also has 
the ability to bind the enhancer region of target 
genes as a GGAA/T core motif.  The acidic domain 
and glutamine-rich domain are thought to activate 
transcriptional ability2.  Over 30 species of the ets-
family have been identiﬁed, and E1AF is catego-
rized as a PEA 3 member with ER81 and ERK3. 
E1AF has been shown to be located on 17q21, and 
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Abstract : Multiple gene disorders have been shown to be involved in carcinogenesis.  Mutation, 
translocation and ampliﬁcation have been identiﬁed in so-called oncogenes, and inactivation of an-
tioncogenes by mutation and deletion has been shown.  E1AF is an ets-oncogene family transcrip-
tion factor, and has been shown to upregulate multiple matrix metalloproteinase (MMP) genes that 
contribute to the malignant phenotype of cancer cells by inducing invasive and metastatic activi-
ties.  EWS/ETS fusions are frequently observed in Ewing's sarcoma, and we have revealed that 
EWS/ETS chimeric protein activates telomerase activity by upregulating human telomerase re-
verse transcriptase (hTERT), but the transcriptional activation of hTERT by EWS/ETS was indi-
rect, and EWS/ETS was seen to function as a co-activator for TERT transcription.  A number of on-
cogenes and cancer-related genes contain AU-rich element (ARE) in non-coding regions of 
transcribed mRNA.  HuR is a RNA-binding protein that has the potential to stabilize ARE-contain-
ing mRNAs.  HuR is known to shuttle between the nucleus and the cytoplasm via several export 
pathways.  When normal cells are exposed to stress, HuR is exported to the cytoplasm in a chromo-
some maintenance region 1 (CRM1)-dependent manner.  However, we demonstrate that HuR is 
CRM-1 independently exported to the cytoplasm in oral cancer cells.  ARE-mRNAs were also ex-
ported to the cytoplasm and stabilized in the oral cancer cells, which were inhibited by HuR knock-
down.  These ﬁndings suggest that transcriptional and translational abnormalities of oncogenes 
may contribute to the carcinogenesis of oral epithelial cells.
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the chromosomal translocation of E1AF has been 
identiﬁed in Ewing's sarcoma and undifferentiated 
sarcoma that had a chimera gene between EWS 
and E1AF 4,5.  From these observations/results, 
an oncogenic property of E1AF is proposed.
　Once the genome-project was over, the impor-
tance of non-coding RNA then became recognized. 
AU-rich element (ARE) is commonly present in 
the 3'-untranslated region of mRNAs of many 
proto-oncogenes, growth factors and cytokines6,7. 
Multiple copies of the sequence AUUUA often 
exist in the ARE and AUF-1 or other RNA degrad-
ing enzymes target ARE-mRNAs for rapid degra-
dation6-8.  HuR is a member of the embryonic 
lethal abnormal vision (ELAV) family of RNA-
binding proteins, which has three RNA recognition 
motifs connected by a short hinge region9.  HuR 
binds to AREs in order to protect ARE-mRNAs 
from rapid degradation8, and a HuR-pp32 complex 
is utilized to transport the ARE-containing 
mRNAs from the nucleus to the cytoplasm via the 
export receptor chromosome maintenance region 1 
(CRM1) under cellular stress loaded conditions 
such as heat shock or serum stimulation, 10,11.  In 
the cells transformed by adenovirus oncogene 
product, ARE-mRNAs and their associated pro-
teins such as HuR and pp32 are exported to the 
cytoplasm in a CRM1-independent manner12.  It 
is therefore of interest to investigate the export 
pathway of ARE-mRNA and its binding partner 
proteins in non-virus mediated tumor cells.  We 
provide evidence that HuR with ARE-mRNA is 
exported to the cytoplasm simultaneously in oral 
cancer cells, and that leptomycin B (LMB) treat-
ment fails to inhibit HuR export13.  These data 
indicate that HuR and ARE-mRNAs are exported 
to the cytoplasm in oral cancer cells in a manner 
different from normal cells.  Additionally, these 
ﬁndings indicate that this HuR export can be used 
as a diagnostic marker for oral cancers.
E1AF is activated downstream of hepatocyte 
growth factor (HGF) and is responsible for 
cancer cell invasion by upregulating matrix 
metalloproteinase (MMP) genes
　HGF is known as the scatter factor, and is 
thought to play a role in cell motility and inva-
sion14.  We examined the effect of HGF on E1AF 
and MMP gene expression in terms of the invasive 
potential of the oral squamous cell carcinoma 
(OSCC) cell line HSC3.  It was found that HGF 
stimulated expression of the E1AF gene15.  We 
introduced the E1AF gene into VMRC-LCD and 
NCI-H226, non-small cell lung carcinoma (NSCLC) 
cell lines lacking E1AF expression, and examined 
the role of E1AF in HGF stimulation.  HGF stimu-
lated the motile and invasive activities in E1AF-
transfected VMRC-LCD and NCI-H226 cells but 
not in their parental or vector-transfected control 
cells.  HGF was found to induce expression of 
urokinase-type plasminogen activator (uPA) genes 
speciﬁcally in E1AF-transfected cells16.
　Matrix metalloproteinase (MMP) has been 
shown to play a key role in helping cancer cells to 
invade through the extracellular matrix and to 
form metastatic lesions.  Generally, MMPs are 
synthesized as a proform, and enzyme activation 
is achieved by removal of the N-terminal propep-
tide domain through exogenous or autocatalytic 
cleavage17,18.  The transcription regulatory regions 
of MMP genes often contain binding motifs for ets 
as well as other transcription factors such as AP1, 
SP1 and NFkB19.  The levels of MMP-1, MMP-3 
and MMP-9 mRNAs were found to increase in 
cells treated with HGF and correlated with E1AF 
upregulation.  In contrast, obvious upregulation of 
MMP-1 and MMP-9 mRNA by HGF was not 
observed in ASE1AFHSC3 cells transfected with 
the antisense E1AF expression vector into paren-
tal HSC3 cells.  The wild-type MMP-9 gene pro-
moter was activated by endogenous E1AF in 
HSC3 cells, and chloramphenicol acetyltrans-
ferase (CAT) activity increased when HGF was 
added to transfected cells.  On the other hand, 
CAT activity was reduced to almost two-thirds 
that of wild-type activity when HSC3 cells were 
transfected with a CAT reporter plasmid driven by 
a mutant MMP-9 promoter lacking the Ets-bind-
ing site.  Moreover, induction of CAT activity was 
not observed upon addition of HGF15.  These 
results suggest that HGF induces expression of 
the Ets-related E1AF transcription factor gene 
whose product in turn activates MMP genes and 
promotes the invasion of OSCCs and NSCLCs.
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　We investigated the transcriptional activity of 
E1AF on MMP-1, -3, and -9 genes in transient 
expression assays. E1AF can up-regulate pro-
moter activities of MMP-1, -3 and -9 in a dose-
dependent manner20.  HSC3, a highly invasive 
oral SCC-derived cell line, was shown to have cor-
relative E1AF and MMP-1, -9 expression21, and 
transfection of the E1AF expression vector into 
MCF7, a weakly invasive human breast cancer 
cell line, results in induction of cells with invasive 
and motile activities accompanied by an increase 
of 92 kDa type IV collagenase (MMP-9) gene 
expression22.  We reconstructed an E1AF anti-
sense expression vector, transfected HSC3 cells 
with the vector, and obtained HSC3AS cells that 
expressed E1AF antisense RNA.  HSC3AS showed 
decreasing mRNA and protein levels of MMP-1, -3 
and -9.  Moreover, HSC3AS showed lower invasive 
potential in in vitro three-dimensional raft cul-
tures and in vivo implantation into nude mice23. 
These results imply that E1AF positively partici-
pates in epithelial cancer cell invasion by upregu-
lating MMP genes.
　The correlation of E1AF expression and cancer 
cell malignancies in in vivo tumors was also 
shown.  E1AF expression in resected tumors of 
NSCLCs was analyzed by Northern blot and in 
situ hybridization, and it was found that 12 out of 
19 tumors expressed E1AF mRNA, while normal 
lung tissue and concomitant normal cells within 
tumors did not16.  Twenty-seven samples from 
OSCC patients were examined using RT-PCR, 
Southern blot hybridization and in situ hybridiza-
tion (ISH).  E1AF mRNA was detected in 15 of 
the 27 cases, and 13 of 17 E1AF positive OSCCs 
showed invasive phenotype, whereas the majority 
of OSCCs not expressing E1AF showed an expan-
sive growth pattern.  Increased prevalence of 
E1AF-positive OSCC was observed in cases with 
nodal metastasis24.  These results indicate that 
E1AF may be involved in cancer cell malignancies 
through its ability to promote invasive potential 
(Fig. 1).
EWS/ETS fusions activate telomerase activity 
to induce cell immortalization
　Ewing's sarcoma is an aggressive bone neopla-
sia mostly occurring in young adults and adoles-
cents.  It is composed of undifferentiated small 
round tumor cells that are thought to derive from 
neural crest progenitors.  These tumors are char-
acterized by speciﬁc chromosomal translocations 
wherein the EWS gene on chromosome 22 is fused 
to one of ﬁve members of the ETS gene family 
(FLI1, ERG, ETV1/ER81, E1AF/PEA3, FEV)25. 
These translocations produce ﬁve chimeric pro-
teins that include the N-terminal transactivation 
domain of EWS and the C-terminal DNA binding 
domain of ETS family transcription factors26. 
EWS/E1AF was found to be the gene responsible 
for tumorigenesis in Ewing's sarcoma; however, 
the transforming activity and the tumorigenic 
mechanism of EWS/E1AF have remained unclear. 
Mammalian telomeres are composed of the 
sequence 5'-TTAGGG-3' that caps the ends of lin-
ear chromosomes.  Telomere shortening causes 
replicative senescence in most somatic cells, and 
increases genetic instability and tumor formation 
in mice26.  Telomeres in most tumor cells maintain 
a certain length, probably as a result of the func-
Fig. 1　E1AF correlates with cancer cell invasion and metastasis with matrix metalloproteinases 
(MMPs) upregulation.
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tion of telomerase, but the relation between telom-
erase and Ewing's family tumors is still unknown. 
Telomerase is able to add telomeric repeats to 
the chromosomes through its enzymatic activity. 
hTERT, in particular, is a catalytic subunit of 
telomerase capable of inducing in vitro and in vivo 
telomerase activities and immortalizing cells27. 
Telomerase activity is tightly regulated at the 
transcriptional level of hTERT, and the expression 
depends on the proximal 181bp region of the pro-
moter in cancer cells28.  This promoter region con-
tains E-boxes, GC-boxes and an ETS binding site 
(EBS), as well as putative binding sites of Myc, 
Sp1 and ETS transcription factors, respectively, 
which are highly conserved between the human 
and mouse promoters.  Myc and other transcrip-
tion factors were reported to regulate hTERT 
expression29, but the ETS oncogene involvement 
in hTERT was obscure.  We found that EWS/ETS 
fusion activated telomerase in Ewing's sarcoma 
cells.  EWS/ETS appears to activate the transcrip-
tion of hTERT, and knock down of EWS/FLI1 
by RNAi leads to the reduction of hTERT mRNA 
and telomerase activity.  However, substitution ets 
binding site (EBS) mutants did not affect the 
responsiveness to EWS/E1AF.  These data indi-
cated that EBS was not the direct target of EWS/
ETS.  To conﬁrm whether EWS/ETS was included 
in the transcriptional initiation complex, we per-
formed DNA-IP assays and found that the com-
plexes contained EWS/E1AF that bound to the 
hTERT promoter.  These results strongly sug-
gested that TERT is one of the targets of EWS/
ETS fusions for its oncogenic activity, and that 
EWS/ETS functions as a co-activator for TERT 
transcription30 (Fig. 2).
HuR translocates into cytoplasm and stabi-
lizes ARE-mRNA in oral cancer cells
　Transcription of oncogenic mRNA is a crucial 
step of carcinogenesis ; however, transcribed mRNA 
stabilization and mRNA transport from nucleus to 
cytoplasm is essential for translation and func-
tional protein expression.  HuR was identiﬁed as 
a binding protein of ARE-mRNA and has been 
shown to stabilize ARE mRNA10,12.  HuR localiza-
tion in oral cancer cells was investigated immuno-
histochemically (HSC-3 ; tongue carcinoma and 
Ca9.22 ; gingival carcinoma).  Both the cytoplasm 
and nucleus positive HuR expression were observed 
in oral cancer cells.  Western blotting by separat-
ing proteins into cytoplasmic and nuclear fractions 
showed that the amounts of HuR in the cytoplasm 
of HSC-3 and Ca9.22 cells were much higher than 
those observed in the cytoplasm of normal cells. 
ARE-mRNA of c-fos and c-myc localization was 
investigated by in situ hybridization.  c-fos and 
c-myc mRNAs were detected in the nucleus and 
cytoplasm of HSC-3 and Ca9.22 cells, but were 
localized only in the nucleus of normal human gin-
Fig. 2　Possible roles of transcription factor complexes. The members in transcription factor complex 
may activate or repress the transcription, and choose the direction of transcription.
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gival ﬁbroblast cells.  We have previously reported 
that the exported ARE-mRNA is stabilized in cells 
transformed with adenovirus E4orf6 12.  The stabi-
lization of c-myc, an ARE-mRNA in oral cancer 
cells, was examined by quantitative real-time RT-
PCR.  Accumulation of the ARE-mRNAs was 
greater in oral cancer cells, and the half-life of the 
mRNA was longer than that of normal cells.
　HuR is known to be exported to the cytoplasm 
in a manner dependent on CRM1 (a member of 
the exportin family of nuclear transporters) when 
cells are stimulated by heat shock or serum stimu-
lation10,11.  On the other hand, HuR and ARE-
mRNAs are known to be exported to the cytoplasm 
via a CRM1-independent pathway in cells trans-
formed by an adenovirus oncogene product12.  In 
order to study the export pathway of HuR in oral 
cancer cells, cells were treated with LMB, an 
inhibitor of CRM1.
　Immunoﬂuorescence analysis showed that the 
accumulation of HuR in the cytoplasm in the oral 
cancer cells was not inhibited with LMB, and the 
existence of HuR was observed in the cytoplasm 
by Western blotting even after the treatment of 
cells with LMB13.  These data indicate that, in 
oral cancer cells, HuR is exported to the cytoplasm 
by perturbing the physiological CRM-dependent 
export machinery.
　To explore the role of HuR for the export and 
stabilization of ARE-mRNA in cancer cells, HSC-3 
cells were subjected to HuR knockdown.  In HuR-
knockdown cells, c-myc mRNA was in the nucleus 
or perinuclear region, and the quantity of c-myc 
mRNA decreased in the HuR-knockdown cells. 
HuR-knockdown cells failed to grow in anchorage-
independent conditions and their motile and 
invasive activities were decreased.  Moreover, the 
expression of cell cycle-related proteins such as 
cyclin A, cyclin B1 and cyclin D1 was reduced31. 
These results suggest that HuR plays a crucial 
role in the stabilization and transport of ARE-
mRNA in oral cancer cells (Fig. 3).
Prospects
　Oncogenic mRNA transcription and translation 
are known to be involved in carcinogenesis includ-
ing oral carcinomas.  Transcription factors have 
functional DNA binding domains that bind to the 
regulatory regions of target genes and activating 
domains that have the property to activate tran-
scription.  Transcription is also controlled by tran-
scriptional co-factors such as CBP/p300 that assist 
Fig. 3　HuR is a key regulator of ARE-mRNA stabilization and transport from nucleus to cytoplasm. 
ARE-mRNAs have roles to maintain cells in emergencies, and disruption of physiological ARE-
mRNA exportation may lead to carcinogenesis.
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the activity of transcription factors32.  Transcrip-
tion factors have been shown to form complexes ; 
for example, AP-1 is a heterodimer of c-fos and 
c-myc that has a very powerful effect on tran-
scription33.  The genome project has been com-
pleted and the number of transcribed genes was 
shown to be smaller than expected34.  The impor-
tance of protein-protein interaction has been high-
lighted, and several non-coding RNAs have been 
discovered to regulate transcription and transla-
tion35.  We found that an ets-family transcription 
factor E1AF is closely concerned with oral carcino-
genesis.  Our ﬁndings that EWS/ETS acts as a 
transcriptional co-factor may imply that the tran-
scription pathway is regulated by the interaction 
of transcription factors.  Moreover, our results 
indicate that the signiﬁcance of the transcribed 
mRNA transport mechanism from nucleus to cyto-
plasm is an essential factor for oral carcinogene-
sis, and shows the possibility that HuR is a potent 
target of gene therapy of oral carcinoma.
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